ABBV AbbVie Inc.

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

The Vanguard Group, Inc. (IRSH)
Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

19-Feb-2020 / 14:14 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Ap19

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH IN INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY INFORMATION

 

Name of person dealing (Note 1)

The Vanguard Group, Inc.

Company dealt in

AbbVie plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

US$0.01 common stock

Date of dealing

18 February 2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

123,299,436

8.34%

39,403

0.00%

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

123,299,436

8.33%

39,403

0.00%

           

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Numbers

(%)

Numbers

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

 

 

 

Ap20

 

1.  Dealings (Note 4)

 

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 5)

Sale

4,100

94.05 USD

Purchase

17,253

94.05 USD

 

 

(b)  Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Not Applicable

 

 

 

 

 

(c)  Options transactions in respect of existing relevant securities

 

(i)  Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

Not Applicable

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

Not Applicable

 

 

 

 

(e)  Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Not Applicable

 

 

Ap21

 

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                           NO

 

Date of disclosure

19 February 2020

Contact name

Shawn Acker

Telephone number

001-610-669-8989

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 

 



Category Code: RET - AbbVie plc
TIDM: IRSH
LEI Code: 5493002789CX3L0CJP65
Sequence No.: 47776
EQS News ID: 979223

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=979223&application_name=news&site_id=research_pool
EN
19/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AbbVie Inc.

AbbVie Inc.: Key facts and statistics - LTM June 2024

A summary company profile, detailing AbbVie Inc.’s business operations and financial highlights.

AbbVie Inc. - June 2024 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Abbvie Inc: 1 director

A director at Abbvie Inc sold 66,500 shares at 186.520USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

AbbVie Inc.: Update to credit analysis following outlook revision to p...

Our credit view of this issuer reflects its articulated target of 2x net debt / EBITDA, against its ongoing earnings erosion through 2024 due to US biosimilar competition for Humira.

Moody's Ratings affirms AbbVie's A3 ratings; revises outlook to positi...

Moody's Ratings (Moody's) affirmed the ratings of AbbVie Inc. ("AbbVie") including the A3 senior unsecured notes, A3 issuer rating and the Prime-2 senior unsecured commercial paper rating. At the same time, we revised AbbVie's outlook to positive from stable. The change in AbbVie's outlook to posi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch